Parameters | PI associated resistance mutations | |
---|---|---|
PI (+) N = 13 | PI (-) N = 28 | |
Age of study entry (Mean+/-SD, years) | 10.2+/-5.2 | 10.6+/-2.7 |
Length of treatment (Mean+/-SD, years) | 6.9+/-3.4 | 6.2+/-2.7 |
NNRTI therapy | 9 (69.2%) | 12 (42.9%) |
TAMs mutations | 10 (76.9%) | 18 (64.3%) |
3TC mutations | 9 (64.2%) * | 9 (32.1%) |
NNRTI mutations | 6 (46.1%) | 12 (42.9%) |
PI (secondary) | 10 (76.9%) *** | 15 (53.5%) |
Clinical categories # | ||
B | 6 (46.1) | 12/27 (44.4%) |
C | 7 (53.9%) | 15/27 (55.6%) |
Immune categories ## | ||
1 (no suppression) | 8 (61.5%) | 16 (57.1%) |
2–3 (moderate/severe) | 5 (28.5%) | 12 (42.9%) |
PVL (n, %) | ||
<10,000 | 1 (7.7%) ** | 14 (50.0%) |
≥ 10,000 | 12 (92.3%) | 14 (50.0%) |